Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Response to Letter]

Shuqin Chen1 Department of Endocrinology and Metabolism, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of China

https://orcid.org/0000-0002-6654-4938

Xuepeng Wang2 Department of Infectious Disease, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of China

Yong Jin3 Department of Internal Medicine, Ningbo Yinzhou No. 2 Hospital, Ningbo, People’s Republic of China

Xueqin Chen4 Department of Traditional Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of China

Qifa Song5 Medical Data Center, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of China

https://orcid.org/0000-0001-9753-2924

Gang Wei6 Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence[email protected]

Li Li1 Department of Endocrinology and Metabolism, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of ChinaCorrespondence[email protected]

https://orcid.org/0000-0001-6301-3544

show all

References

Chen S, Wang X, Jin Y, et al. Assessment of changes in body composition after 3 months of dulaglutide treatment. Diabetes Metab Syndr Obes. 2024;17:1301–1308. doi:10.2147/DMSO.S443631
PubMed Web of Science ®Google Scholar
Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13(5):418–425. doi:10.1111/j.1463-1326.2011.01366.x
PubMed Web of Science ®Google Scholar
Li Y, Li L, De Peng Y, et al. Efficacy and safety of dulaglutide versus insulin glargine in Chinese T2DM patients: a subgroup analysis of a randomized trial (AWARD-CHN2). Diabetes Ther. 2019;10(4):1435–1452. doi:10.1007/s13300-019-0646-y
PubMed Web of Science ®Google Scholar
Li Y, Gong X, Găman M-A, Hernández-Wolters B, Velu P, Li Y. The effect of subcutaneous dulaglutide on weight loss in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Eur J Clin Invest. 2024;54(4):e14125. doi:10.1111/eci.14125
PubMed Web of Science ®Google Scholar
Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021;44(3):765–773. doi:10.2337/dc20-1473
PubMed Web of Science ®Google Scholar

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Response to Letter]

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Response to Letter]

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date